The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its blockbuster drug Wegovy.

In this video, I will explain why Hims & Hers Health (NYSE: HIMS) crashed over 30% on Monday. Watch the short video to learn more, consider subscribing, and click the special offer link below. *Stock ...

Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell ...

Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock is a Hold.

The home builder says it has worked to lower its build times and reduce direct construction costs as it navigates softer market conditions. The airline's relisting comes against the backdrop of an ...

Teladoc Health stock price surged by over 14% on Monday, its best single-day gain since April 9. What next for the TDOC share ...

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...

On Monday, major U.S. indices ended the day in the green with the Dow Jones Industrial Average rising 0.9% to 42,581.78, and the S&P 500 gaining nearly 1% to 6,025.17.

Energy stocks posted declines after the [U.S. attacked Iranian nuclear facilities](http ...

The calming in the oil market came as several analysts said Iran would likely refrain from closing the waterway. Iran itself ...

Hims & Hers Health Inc.'s stock booked record losses Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the telehealth ...